Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

FSAP-mediated nucleosome release from late apoptotic cells is inhibited by autoantibodies present in SLE.

Marsman G, Stephan F, de Leeuw K, Bulder I, Ruinard JT, de Jong J, Westra J, Bultink IE, Voskuyl AE, Aarden LA, Luken BM, Kallenberg CG, Zeerleder S.

Eur J Immunol. 2016 Mar;46(3):762-71. doi: 10.1002/eji.201546010. Epub 2015 Dec 22.

2.

Response to: 'The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region' by Rinaudo-Gaujous et al.

van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T.

Ann Rheum Dis. 2015 Aug;74(8):e41. doi: 10.1136/annrheumdis-2015-207529. Epub 2015 Apr 8. No abstract available.

PMID:
25854585
3.

The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region.

van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T.

Ann Rheum Dis. 2015 Jan;74(1):311-4. doi: 10.1136/annrheumdis-2014-206237. Epub 2014 Oct 23.

PMID:
25342759
4.

Cooperation of factor VII-activating protease and serum DNase I in the release of nucleosomes from necrotic cells.

Stephan F, Marsman G, Bakker LM, Bulder I, Stavenuiter F, Aarden LA, Zeerleder S.

Arthritis Rheumatol. 2014 Mar;66(3):686-93. doi: 10.1002/art.38265.

5.

Tissue factor pathway inhibitor is an inhibitor of factor VII-activating protease.

Stephan F, Dienava-Verdoold I, Bulder I, Wouters D, Mast AE, Te Velthuis H, Aarden LA, Zeerleder S.

J Thromb Haemost. 2012 Jun;10(6):1165-71. doi: 10.1111/j.1538-7836.2012.04712.x.

6.

FSAP, a new player in inflammation?

Stephan F, Aarden LA, Zeerleder S.

Hamostaseologie. 2012;32(1):51-5. doi: 10.5482/ha-1187. Review.

PMID:
22252569
7.

Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing.

Rispens T, de Vrieze H, de Groot E, Wouters D, Stapel S, Wolbink GJ, Aarden LA.

J Immunol Methods. 2012 Jan 31;375(1-2):93-9. doi: 10.1016/j.jim.2011.09.011. Epub 2011 Oct 1.

PMID:
21986105
8.

Differential effect of drug interference in immunogenicity assays.

Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, Aarden LA, Rispens T.

J Immunol Methods. 2011 Sep 30;372(1-2):196-203. doi: 10.1016/j.jim.2011.07.019. Epub 2011 Jul 29.

PMID:
21824477
9.

Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18952) and prognostic value on treatment outcome.

Bouwhuis MG, Collette S, Suciu S, de Groot ER, Kruit WH, Ten Hagen TL, Aarden LA, Eggermont AM, Swaak AJ; EORTC Melanoma Group.

Melanoma Res. 2011 Aug;21(4):344-51. doi: 10.1097/CMR.0b013e328346c17f.

PMID:
21546857
10.

Activation of factor VII-activating protease in human inflammation: a sensor for cell death.

Stephan F, Hazelzet JA, Bulder I, Boermeester MA, van Till JO, van der Poll T, Wuillemin WA, Aarden LA, Zeerleder S.

Crit Care. 2011;15(2):R110. doi: 10.1186/cc10131. Epub 2011 Apr 5.

11.

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.

Rispens T, Leeuwen Av, Vennegoor A, Killestein J, Aalberse RC, Wolbink GJ, Aarden LA.

Anal Biochem. 2011 Apr 15;411(2):271-6. doi: 10.1016/j.ab.2011.01.001. Epub 2011 Jan 7.

PMID:
21216215
12.

Intravenous clusterin administration reduces myocardial infarct size in rats.

Van Dijk A, Vermond RA, Krijnen PA, Juffermans LJ, Hahn NE, Makker SP, Aarden LA, Hack E, Spreeuwenberg M, van Rossum BC, Meischl C, Paulus WJ, Van Milligen FJ, Niessen HW.

Eur J Clin Invest. 2010 Oct;40(10):893-902. doi: 10.1111/j.1365-2362.2010.02345.x.

PMID:
20854280
13.

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.

de Vries MK, Brouwer E, van der Horst-Bruinsma IE, Spoorenberg A, van Denderen JC, Jamnitski A, Nurmohamed MT, Dijkmans BA, Aarden LA, Wolbink GJ.

Ann Rheum Dis. 2009 Nov;68(11):1787-8. doi: 10.1136/ard.2009.109702. No abstract available.

PMID:
19822712
14.

Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma.

Damen CW, de Groot ER, Heij M, Boss DS, Schellens JH, Rosing H, Beijnen JH, Aarden LA.

Anal Biochem. 2009 Aug 15;391(2):114-20. doi: 10.1016/j.ab.2009.05.030. Epub 2009 May 22.

PMID:
19464994
15.

Dealing with immunogenicity of biologicals: assessment and clinical relevance.

Wolbink GJ, Aarden LA, Dijkmans BA.

Curr Opin Rheumatol. 2009 May;21(3):211-5. Review.

PMID:
19399992
16.

High-throughput analysis of the C4 polymorphism by a combination of MLPA and isotype-specific ELISA's.

Wouters D, van Schouwenburg P, van der Horst A, de Boer M, Schooneman D, Kuijpers TW, Aarden LA, Hamann D.

Mol Immunol. 2009 Feb;46(4):592-600. doi: 10.1016/j.molimm.2008.07.028. Epub 2008 Dec 5.

PMID:
19062096
17.

Effects of smoking on the ex vivo cytokine production in periodontitis.

de Heens GL, Kikkert R, Aarden LA, van der Velden U, Loos BG.

J Periodontal Res. 2009 Feb;44(1):28-34. doi: 10.1111/j.1600-0765.2007.01047.x. Epub 2008 Oct 29.

PMID:
18973517
18.

Nucleosome-releasing factor: a new role for factor VII-activating protease (FSAP).

Zeerleder S, Zwart B, te Velthuis H, Stephan F, Manoe R, Rensink I, Aarden LA.

FASEB J. 2008 Dec;22(12):4077-84. doi: 10.1096/fj.08-110429. Epub 2008 Aug 27.

PMID:
18753248
19.

[The formation of infliximab and anti-infliximab immune complexes as an explanation for non-responding to infliximab treatment of rheumatoid arthritis: observational study in 4 patients].

van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink GJ, Dijkmans BA, Aarden LA.

Ned Tijdschr Geneeskd. 2008 Jul 26;152(30):1672-7. Dutch.

PMID:
18714521
20.

Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network.

Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS.

Cell. 2008 Jun 13;133(6):1019-31. doi: 10.1016/j.cell.2008.03.039.

21.

Cytokine induction by pyrogens: comparison of whole blood, mononuclear cells, and TLR-transfectants.

Kikkert R, de Groot ER, Aarden LA.

J Immunol Methods. 2008 Jul 20;336(1):45-55. doi: 10.1016/j.jim.2008.03.010. Epub 2008 Apr 22.

PMID:
18456276
22.

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.

de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, van Denderen JC, Dijkmans BA, Wolbink GJ.

Ann Rheum Dis. 2009 Apr;68(4):531-5. doi: 10.1136/ard.2008.089979. Epub 2008 Mar 28.

PMID:
18375542
23.

A plasma nucleosome releasing factor (NRF) with serine protease activity is instrumental in removal of nucleosomes from secondary necrotic cells.

Zeerleder S, Zwart B, te Velthuis H, Manoe R, Bulder I, Rensink I, Aarden LA.

FEBS Lett. 2007 Nov 27;581(28):5382-8. Epub 2007 Oct 30.

24.

Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange.

van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, van de Winkel JG, Aalberse RC, Parren PW.

Science. 2007 Sep 14;317(5844):1554-7.

25.

Potentiation of Toll-like receptor-induced cytokine production by (1-->3)-beta-D-glucans: implications for the monocyte activation test.

Kikkert R, Bulder I, de Groot ER, Aarden LA, Finkelman MA.

J Endotoxin Res. 2007;13(3):140-9.

PMID:
17621556
26.

Activation of toll-like receptors 2 and 4 by gram-negative periodontal bacteria.

Kikkert R, Laine ML, Aarden LA, van Winkelhoff AJ.

Oral Microbiol Immunol. 2007 Jun;22(3):145-51.

PMID:
17488439
27.

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.

de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE.

Ann Rheum Dis. 2007 Sep;66(9):1252-4. Epub 2007 May 1.

28.

Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.

de Vries MK, Wolbink GJ, Stapel SO, de Groot ER, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE.

Ann Rheum Dis. 2007 Jan;66(1):133-4. No abstract available.

29.

Variable mannose-binding lectin expression during postoperative acute-phase response.

Van Till JW, Boermeester MA, Modderman PW, Van Sandick JW, Hart MH, Gisbertz SS, Van Lanschot JJ, Aarden LA.

Surg Infect (Larchmt). 2006 Oct;7(5):443-52.

PMID:
17083310
30.

Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis.

van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G, Dijkmans BA, Aarden LA.

Ann Rheum Dis. 2007 Feb;66(2):253-6. Epub 2006 Jun 22.

31.

Mannan-binding lectin (MBL)-mediated opsonization is enhanced by the alternative pathway amplification loop.

Brouwer N, Dolman KM, van Zwieten R, Nieuwenhuys E, Hart M, Aarden LA, Roos D, Kuijpers TW.

Mol Immunol. 2006 May;43(13):2051-60. Epub 2006 Feb 24.

PMID:
16499969
32.

High-affinity antibodies in a new immunoassay for plasma tissue factor: reduction in apparent intra-individual variation.

van der Putten RF, te Velthuis H, Aarden LA, ten Cate H, Glatz JF, Hermens WT.

Clin Chem Lab Med. 2005;43(12):1386-91.

PMID:
16309378
33.

State and diagnostic value of plasma tissue factor in early-hospitalised patients with chest pain.

van der Putten RF, te Velthuis HT, de Zwaan C, Aarden LA, Glatz JF, Hermens WT.

Br J Haematol. 2005 Oct;131(1):91-9.

PMID:
16173968
34.

Clusterin: a protective mediator for ischemic cardiomyocytes?

Krijnen PA, Cillessen SA, Manoe R, Muller A, Visser CA, Meijer CJ, Musters RJ, Hack CE, Aarden LA, Niessen HW.

Am J Physiol Heart Circ Physiol. 2005 Nov;289(5):H2193-202. Epub 2005 Jul 1.

35.

4-Hydroxy-oxyphenbutazone is a potent inhibitor of cytokine production.

Ten Brinke A, Dekkers DW, Notten SM, Karsten ML, de Groot ER, Aarden LA.

Eur Cytokine Netw. 2005 Jun;16(2):144-51.

36.

Two inhibitors of DNA-synthesis lead to inhibition of cytokine production via a different mechanism.

de Lathouder S, Gerards AH, Dijkmans BA, Aarden LA.

Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1089-100. Review.

PMID:
15571208
37.

Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells.

Zwart B, Ciurana C, Rensink I, Manoe R, Hack CE, Aarden LA.

Autoimmunity. 2004 Mar;37(2):95-102.

PMID:
15293879
38.

Bioassay for detection of methotrexate in serum.

de Lathouder S, Gerards AH, de Groot ER, Valkhof MG, Dijkmans BA, Aarden LA.

Scand J Rheumatol. 2004;33(3):167-73.

PMID:
15228187
39.

Mannan binding lectin in febrile adults: no correlation with microbial infection and complement activation.

Tacx AN, Groeneveld AB, Hart MH, Aarden LA, Hack CE.

J Clin Pathol. 2003 Dec;56(12):956-9.

40.
41.

Elevated nucleosome levels in systemic inflammation and sepsis.

Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, Groeneveld AB, Caliezi C, van Nieuwenhuijze AE, van Mierlo GJ, Eerenberg AJ, Lämmle B, Hack CE.

Crit Care Med. 2003 Jul;31(7):1947-51.

PMID:
12847387
42.

Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis.

Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA.

Rheumatology (Oxford). 2003 Oct;42(10):1189-96. Epub 2003 May 30.

PMID:
12777636
43.
44.

Mycophenolic acid and methotrexate inhibit lymphocyte cytokine production via different mechanisms.

de Lathouder S, Gerards AH, de Groot ER, Valkhof M, Aarden LA.

Eur Cytokine Netw. 2002 Jul-Sep;13(3):317-23.

45.

FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection.

Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, van Lent PL, Hofhuis FM, van Ojik HH, Sedlik C, da Silveira SA, Gerber J, de Jong YF, Roozendaal R, Aarden LA, van den Berg WB, Saito T, Mosser D, Amigorena S, Izui S, van Ommen GJ, van Vugt M, van de Winkel JG, Verbeek JS.

Immunity. 2002 Mar;16(3):391-402.

46.

High IL-13 production by human neonatal T cells: neonate immune system regulator?

Ribeiro-do-Couto LM, Boeije LC, Kroon JS, Hooibrink B, Breur-Vriesendorp BS, Aarden LA, Boog CJ.

Eur J Immunol. 2001 Nov;31(11):3394-402.

47.

Chromatin-independent binding of serum amyloid P component to apoptotic cells.

Familian A, Zwart B, Huisman HG, Rensink I, Roem D, Hordijk PL, Aarden LA, Hack CE.

J Immunol. 2001 Jul 15;167(2):647-54.

48.

An IL-13 promoter polymorphism associated with increased risk of allergic asthma.

van der Pouw Kraan TC, van Veen A, Boeije LC, van Tuyl SA, de Groot ER, Stapel SO, Bakker A, Verweij CL, Aarden LA, van der Zee JS.

Genes Immun. 1999 Sep;1(1):61-5.

49.

Soluble CD95 concentrations are increased in patients with severe systemic lupus erythematosus, but not in their first degree relatives.

van der Linden MW, van Lopik T, Aarden LA, Westendorp RG, Huizinga TW.

Ann Rheum Dis. 2001 Mar;60(3):237-41.

50.

Functional disparity of distinct CD28 response elements toward mitogenic responses.

Civil A, Rensink I, Aarden LA, Verweij CL.

J Biol Chem. 1999 Nov 26;274(48):34369-74.

Supplemental Content

Loading ...
Support Center